Radiation Dose to Otologic Structures During Head and Neck Cancer Radiation Therapy

Authors

  • Frank G. Ondrey MD, PhD,

    Corresponding author
    1. Head and Neck Surgery Branch of the National Institute on Deafness and Other Communication Disorders, Bethesda, Maryland.
    • Frank G. Ondrey, MD, PhD, Department of Otolaryngology, Box 396, 420 Delaware Street, SE, Minneapolis, MN 55455, U.S.A.

    Search for more papers by this author
  • J. Robert Greig PhD,

    1. Radiation Oncology Branch of the National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
    Search for more papers by this author
  • Laurie Herscher MD

    1. Radiation Oncology Branch of the National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
    Search for more papers by this author

  • Presented at the Meeting of the Middle Section of the American Laryngological, Rhinological and Otological Society, Inc., Minneapolis, Minnesota, January 25, 1998.

Abstract

Background: Otologic structures are often contained within head and neck cancer radiation treatment ports. The dosimetry to otologic structures has not been routinely analyzed and radiation treatment planning does not currently attempt to specifically avoid the inner ear structures when dosimetry is calculated. Recent studies demonstrate that up to 30% of patients experience sensorineural hearing loss on multimodality therapy with cisplatin and radiation.

Methods: In the current case series, radiation dosimetry to otologic structures was calculated from computed tomogram treatment plans on patients. Fifteen nasopharyngeal, oral cavity, oropharyngeal, and hypopharyngeal cancer patients were analyzed.

Results: Between 8% and 102% of the total dose is delivered to the petrous bone/cochlea, with 4 of 15 patients getting more than 50% of the dose to at least one cochlea. The mastoid air cells received between 3% and 75% of the total dose, with higher doses being delivered to patients with bulky high neck metastases or nasopharyngeal tumors. The eustachian tubes received between 2% and 102% of the total dose, with 10 of 15 patients receiving more than 50% of the dose to this anatomic site.

Conclusion: We conclude that the cochlea and eustachian tubes receive significant radiation during treatment, particularly in nasopharyngeal cancer patients. Careful design of radiation treatment ports may allow for the reduction of radiation to hearing structures.

Ancillary